Work

OA03.03 JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti-PD-L1) as First-Line Treatment in Patients with Advanced NSCLC

Year: 2017

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2016.11.240

Authors: Guy Jerusalem, Franklin Chen, David Spigel, Nicholas Iannotti, Edward Mcclay, Charles Redfern, Jaafar Bennouna, Matthew Taylor, Howard Kaufman, Karen Kelly, Vikram Chand, Anja Von Heydebreck, Claire Verschraegen

Institutions: University of Liège, Novant Health, Hematology Oncology Associates, California Cancer Associates for Research and Excellence, Sharp HealthCare, OHSU Knight Cancer Institute, Rutgers Cancer Institute, UC Davis Comprehensive Cancer Center, EMD Serono, Inc. (United States), Merck KGaA, Darmstadt (Germany), University of Vermont

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2569311824

Cites:

Cited by: 22

Related to: 10